TL;DR
This study investigates whether exposure to iodinated contrast media, commonly used in medical imaging, is associated with a reduced risk of contracting COVID-19. The findings suggest that such exposure may indeed offer a protective effect, potentially due to iodine's known antimicrobial properties.
What Problem Does This Paper Address?
The COVID-19 pandemic has spurred extensive research into ways to mitigate its spread and impact. While vaccines and antiviral treatments are primary defenses, exploring readily available and potentially inexpensive interventions remains crucial, especially in regions with limited vaccine access. The authors note that iodine, a well-established antiseptic, has shown in vitro efficacy against SARS-CoV-2. However, there was a lack of real-world data on whether exposure to higher levels of iodine, such as that from medical contrast agents, could translate to a reduced incidence of COVID-19 infection in humans. This paper aims to fill that gap by examining the association between iodinated contrast exposure and subsequent COVID-19 infection in a large veteran population.
Methods
The researchers conducted a retrospective population-level cohort study using data from the U.S. Veterans Health Administration (VHA) between March 2020 and December 2020. This period was chosen to capture data before widespread COVID-19 vaccination.
The core of their methodology involved:
- Cohort Selection: Identifying adult Veterans (≥18 years) with active VHA utilization and at least one COVID-19 test result within the study timeframe. Patients with prior prescriptions for iodine-containing medications were excluded to isolate the effect of contrast media.
- Iodine Exposure Measurement: Iodine exposure was defined by the presence of ICD-9 and ICD-10 codes for radiologic procedures that utilize iodinated contrast media within 60 days prior to a COVID-19 test.
- COVID-19 Infection Measurement: COVID-19 infection was determined by positive results from polymerase chain reaction (PCR) tests. For individuals with multiple negative tests, only the first positive test was considered, with subsequent data censored.
- Statistical Analysis: Multivariable logistic regression models, employing generalized estimating equations, were used to estimate the adjusted odds ratios (OR) and 95% confidence intervals (CI) for the association between iodinated contrast exposure and incident COVID-19 infection. The models controlled for potential confounders including age, sex, race/ethnicity, place of residence, socioeconomic status, and insurance status. Stratified analyses were performed to examine potential differences in the association across age groups, sexes, and racial/ethnic categories.
Datasets
The study utilized the Veterans Affairs (VA) Corporate Data Warehouse (CDW), which serves as the national repository for clinical and administrative records of U.S. Veterans Health Administration (VHA) inpatient and outpatient sites. This dataset provided the basis for identifying patients, their medical procedures (including contrast use), and COVID-19 test results.
Key Insights and Ideas
- Iodine's Antimicrobial Potential in Vivo: The study provides real-world evidence supporting the hypothesis that iodine's antimicrobial properties, previously demonstrated in vitro, may translate to a protective effect against SARS-CoV-2 infection in humans.
- Contrast Media as a Proxy for Iodine Exposure: Iodinated contrast media, used in a significant proportion of imaging procedures, delivers a substantial, albeit transient, iodine load. This makes patients undergoing such procedures a unique cohort to study the effects of high-level iodine exposure.
- Consistent Protective Effect Across Demographics: The observed association between iodinated contrast exposure and reduced COVID-19 risk was consistent across different age groups, sexes, and racial/ethnic categories, suggesting a broad biological effect rather than one specific to certain subgroups.
- Potential for Public Health Intervention: The findings suggest that judicious iodine supplementation, within safe limits, could be a simple and accessible public health strategy to reduce COVID-19 burden, particularly in areas with limited vaccine availability.
Key Results
The study analyzed 530,942 COVID-19 tests from 333,841 Veterans. Approximately 9% of these tests were from patients who had received iodinated contrast within 60 days.
- Overall Association: Iodine exposure was associated with a decreased risk of incident COVID-19 test positivity, with an adjusted odds ratio (OR) of 0.75 (95% CI, 0.71-0.78).
- Stratified Analyses:
- Age: The protective effect was observed in both younger (<65 years, OR 0.79) and older (≥65 years, OR 0.72) age groups.
- Sex: Both males (OR 0.74) and females (OR 0.78) showed a reduced risk.
- Race/Ethnicity: The association was significant across various groups, including Hispanic (OR 0.75), Non-Hispanic White (OR 0.71), and Non-Hispanic Black (OR 0.83) individuals.
Limitations and Future Work
The authors acknowledge several limitations:
- Misclassification Bias: Reliance on ICD codes for identifying radiologic procedures and COVID-19 tests could lead to misclassification.
- Unmeasured Confounders: While many covariates were controlled for, unmeasured factors like comorbidities and their severities could still influence the results.
- Generalizability: The study population was predominantly male (90.2%) due to the VHA cohort. Therefore, the findings may not be fully generalizable to the broader population.
- Iodine Content Variability: The exact amount of iodine in the contrast media administered was not available in the dataset, preventing dose-response analyses.
Future work could involve studies with more detailed information on medical conditions and contrast agent types, as well as investigations into the optimal safe levels of iodine supplementation for antimicrobial benefits. The authors also suggest exploring this protective effect against other enveloped viruses.
Summary updated